White Corina E, Olabisi Ronke M
Department of Biomedical Engineering, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
J Tissue Eng. 2017 Jul 21;8:2041731417720841. doi: 10.1177/2041731417720841. eCollection 2017 Jan-Dec.
In several retinal degenerative diseases, including age-related macular degeneration, the retinal pigment epithelium, a highly functionalized cell monolayer, becomes dysfunctional. These retinal diseases are marked by early retinal pigment epithelium dysfunction reducing its ability to maintain a healthy retina, hence making the retinal pigment epithelium an attractive target for treatment. Cell therapies, including bolus cell injections, have been investigated with mixed results. Since bolus cell injection does not promote the proper monolayer architecture, scaffolds seeded with retinal pigment epithelium cells and then implanted have been increasingly investigated. Such cell-seeded scaffolds address both the dysfunction of the retinal pigment epithelium cells and age-related retinal changes that inhibit the efficacy of cell-only therapies. Currently, several groups are investigating retinal therapies using seeded cells from a number of cell sources on a variety of scaffolds, such as degradable, non-degradable, natural, and artificial substrates. This review describes the variety of scaffolds that have been developed for the implantation of retinal pigment epithelium cells.
在包括年龄相关性黄斑变性在内的几种视网膜退行性疾病中,视网膜色素上皮(一种高度功能化的细胞单层)会出现功能障碍。这些视网膜疾病的特征是早期视网膜色素上皮功能障碍,降低了其维持健康视网膜的能力,因此使视网膜色素上皮成为一个有吸引力的治疗靶点。包括推注式细胞注射在内的细胞疗法已被研究,但结果不一。由于推注式细胞注射不能促进形成合适的单层结构,因此越来越多地研究接种了视网膜色素上皮细胞然后植入的支架。这种接种细胞的支架既解决了视网膜色素上皮细胞的功能障碍,又解决了与年龄相关的视网膜变化,这些变化会抑制单纯细胞疗法的疗效。目前,几个研究小组正在研究使用来自多种细胞来源的接种细胞在各种支架上进行视网膜治疗,这些支架包括可降解、不可降解、天然和人工基质。这篇综述描述了已开发用于植入视网膜色素上皮细胞的各种支架。